Literature DB >> 23217011

Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia.

S Pandey1, S R Post, D V Alapat, K J Smock, G R Post.   

Abstract

INTRODUCTION: Abnormal screening coagulation tests are frequently observed in asymptomatic patients with multiple myeloma and other plasma cell neoplasms.
METHODS: Prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen activity were correlated with clinical history and disease parameters in patients referred to the Myeloma Institute for Research and Therapy.
RESULTS: An isolated prolonged PT was the most common abnormal coagulation test (25%). Prolonged PT was more frequently observed in patients with multiple myeloma (n = 157) compared to MGUS patients (n = 34) or other diagnostic categories of plasma cell dyscrasia. There were no differences in age, gender, previous chemotherapy, or immunoglobulin isotype in patients with isolated prolonged PT (n = 62) compared to those with normal screening coagulation tests (n = 173). Fibrinogen activity was significantly lower in patients with prolonged PT; however, there was no correlation between fibrinogen activity and PT. Serum M protein concentrations were significantly greater in patients with prolonged PT and were positively correlated with PT.
CONCLUSION: An association between disease severity and prolonged PT is suggested by our finding that patients with multiple myeloma were more likely to have prolonged PT than patients with other plasma cell neoplasms. Of the factors examined, the monoclonal protein level was significantly higher in patients with isolated prolonged PT and correlated with PT.
© 2012 John Wiley & Sons Ltd.

Entities:  

Keywords:  Prothrombin time; plasma cell dyscrasia; serum immunoglobulin

Mesh:

Substances:

Year:  2012        PMID: 23217011     DOI: 10.1111/ijlh.12036

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  6 in total

1.  Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Maeve P Crowley; Maeve P Crowely; Shane Quinn; Eoin Coleman; Joseph A Eustace; Oonagh M Gilligan; Susan I O'Shea; Susan I O Shea
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

2.  The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.

Authors:  Chuanying Geng; Guangzhong Yang; Huijuan Wang; Zhiyao Zhang; Huixing Zhou; Wenming Chen
Journal:  Biomed Res Int       Date:  2021-05-19       Impact factor: 3.411

3.  Acquired factor VII inhibitor associated with primary central nervous system Lymphoma: A case report.

Authors:  Vanshika Goyal; Giselle Salmasi; Andrew D Leavitt; James L Rubenstein; Rahul Banerjee
Journal:  EJHaem       Date:  2022-06-07

4.  Multiple myeloma and primary erythrocytosis in a dog.

Authors:  Marianna Ricci; Giulia De Feo; Martin Konar; George Lubas
Journal:  Can Vet J       Date:  2021-08       Impact factor: 1.008

5.  Interference of M-protein on prothrombin time test - case report.

Authors:  Sandra Margetić; Ivana Ćelap; Lora Dukić; Ines Vukasović; Lucija Virović-Jukić
Journal:  Biochem Med (Zagreb)       Date:  2016       Impact factor: 2.313

6.  Hemostatic Abnormalities in Multiple Myeloma Patients

Authors:  Aarti Gogia; Meera Sikka; Satender Sharma; Usha Rusia
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.